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Abstract Primer extension analysis and RNase protection
assays revealed the identity of glucose 6-phosphatase gene
transcripts in both the insulinoma cell line INS-1 and hepatic
cells. In transient transfection assays of INS-1 cells, using
constructs between the human glucose 6-phosphatase gene
promoter and a luciferase reporter gene, the reporter gene
activity was induced by dexamethasone and dibutyryl cAMP.
Furthermore, the promoter was regulated by the glucose
concentration in the medium. This effect was dependent on
glucose metabolism. The data indicated that glucose 6-phospha-
tase gene transcription is regulated in a similar way in the
insulinoma cell line and in liver.
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1. Introduction
Glucose 6-phosphatase catalyses the hydrolysis of glucose
6-phosphate to glucose, which is the ¢nal step of gluconeo-
genesis and glycogen breakdown. The highest activities of the
enzyme can be detected in liver and kidney. The liver enzyme
is embedded in the membrane of the endoplasmic reticulum
and consists of a multi-protein complex formed by transport
proteins and the glucose-6-phosphatase catalytic subunit
(G6Pase) ([1] for review). Hepatic G6Pase gene expression is
induced by glucocorticoids and glucagon during starvation. In
addition, it has been shown that in hepatic cells G6Pase ex-
pression is increased by high concentrations of glucose per se,
i.e. the product of the enzymatic reaction [2,3]. This leads in
hyperglycaemia to an increase of G6Pase activity, which could
be of pathophysiological importance [2,3].
G6Pase activity can also be detected in pancreatic islets
[4,5]. The amount of activity present in these cells is contro-
versial [6^8]. This discrepancy might be caused by the low
stability of islet G6Pase in vitro [6]. The function of the
G6Pase enzyme in pancreatic L-cells is not clear, as islets
are not a gluconeogenic tissue [9]. It has been suggested that
changes of pancreatic G6Pase activity might modulate insulin
release in response to glucose (e.g. [10]). G6Pase catalyses the
opposite reaction to the central enzyme of pancreatic glucose
sensing, glucokinase, resulting in an ATP-consuming substrate
cycle [11,12]. In vitro, the overexpression of the catalytic sub-
unit of G6Pase decreased glucose mediated insulin release [13].
Previous work has shown that G6Pase activity in pancreatic
L-cells is increased by glucocorticoids in vivo [8]. Elevated
glucose cycling has been reported in islets of ob/ob mice and
animal models of type II diabetes [7,11,12,14]. The study of
the regulation of G6Pase in pancreatic islets has been ham-
pered by the cellular heterogeneity of the tissue and the loss of
G6Pase expression in freshly isolated islets during their culti-
vation.
In the present paper we show that glucose has an in£uence
on G6Pase gene transcription in a pancreatic cell line per se,
like in liver. We performed our experiments with the highly
di¡erentiated insulinoma cell line INS-1, which has been well
established for the analysis of regulation of gene expression by
glucose [15^18]. INS-1 cells express only marginal amounts of
glucose 6-phosphatase activity [13]. Therefore, we studied the
regulation of a luciferase reporter gene under the control of
the G6Pase gene promoter.
2. Materials and methods
2.1. Materials
Restriction endonucleases, modifying enzymes, luciferase assay re-
agent, RNase Protection kit and plasmids were purchased from Prom-
ega. Plasmid puri¢cation systems were from Qiagen. All radioisotopes
and the sequencing kit were obtained from Amersham. N6,2P-O-Di-
butyryl cyclic AMP (db2cAMP) was purchased from Boehringer
Mannheim. All other reagents were purchased in analytical grade
either from Sigma or Merck.
2.2. RNA analysis
Total RNA from rat pancreas, INS-1 cells and liver were isolated
by the guanidine thiocyanate method [19]. For RT-PCR 1 Wg total
RNA was transcribed using an oligo-dT primer. G6Pase cDNA was
ampli¢ed by PCR using speci¢c primers designed according to the rat
G6Pase sequence [20]. The sequences of the oligonucleotides are avail-
able upon request. The PCR products were resolved by agarose gel
electrophoresis and transferred onto a nylon membrane (Amersham)
by passive capillary di¡usion. Southern blotting was carried out as
described in [21]. After prehybridisation the ¢lter was hybridised with
a full-length cDNA probe of G6Pase, which was labelled with [K-
32P]dCTP using the ‘Prime-a-gene system’ (Promega) according to
the manufacturer’s instructions. Primer extension analysis was per-
formed using K-32P-labelled oligonucleotide, which hybridises to bp
109^132 of the rat G6Pase mRNA [20]. 500 000 cpm of the primer
were hybridised overnight to 10 Wg (liver) or 40 Wg (INS-1, pancreas)
of total RNA in 100 Wl 40 mM PIPES (pH 6.4), 1 mM EDTA,
400 mM NaCl, 80% (v/v) formamide at 38‡C. Following precipitation
the reverse transcription was carried out as described [21] in a volume
of 20 Wl. RNA was hydrolysed by adding 16 Wl 500 mM NaOH and
incubating for 2 min at 90‡C. Subsequently samples were neutralised
with 8 Wl 1 M HCl. Products were precipitated and analysed on a
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sequencing gel, together with a sequencing reaction as a size marker.
For the RNase protection assay the sequence of the rat G6Pase
cDNA from nucleotide 1 to nucleotide 400 [20] were ampli¢ed by
PCR. The product was cloned into the EcoRI/HindIII site of
pGEM7 using nested restriction sites within the primer sequences.
The template was linearised with EcoRI and in vitro transcription
was performed in the presence of [K-32P]CTP using SP6 polymerase.
500 000 cpm of the riboprobe were hybridised overnight at 50‡C with
5 Wg (liver) or 30 Wg (INS-1) of total RNA in 20 Wl 40 mM PIPES (pH
6.4), 1 mM EDTA, 400 mM NaCl, 80% (v/v) formamide. The probe
contained 50 nucleotides vector sequence, which did not hybridise
with G6Pase cDNA. RNase digestion was performed with 10 U
RNase ONE (Promega) at RT for 60 min using the RNase protection
kit (Promega). Samples were analysed on an 8% polyacrylamide gel.
The undigested probe and the protected fragments were sized by
comparison to PX174 DNA standards (Promega) end-labelled with
[Q-32P]ATP using T4 polynucleotide kinase.
2.3. Reporter gene constructs
The construction of the plasmids pGL3-1.2 and pGL3 (3161/+4)
has been described previously [22] and were created by cloning the
31227/+57 bp or the 3161/+4 bp fragments of the human G6Pase
gene promoter into the XhoI/SacI site of the promoterless vector
pGL3 basic, which contains the luciferase reporter gene.
2.4. Cell culture and transfections
INS-1 cells were cultured as in [23] in the presence of 11 mM
glucose. 36 h before transfection 1U106 cells were seeded in 35 mm
dishes. 4 h before transfection the cells were fed with fresh medium.
Transfections were performed by the calcium phosphate/DNA co-pre-
cipitation method as described [22] using 10 Wg reporter gene con-
struct and 2 Wg pSV-L-galactosidase. 18 h after transfection cells
were glycerol-shocked (15%, 2 min) and incubated for 4 h in
DMEM without serum (5.5 mM glucose). Subsequently, the medium
was changed to DMEM without serum for 20 h in the presence or
absence of db2cAMP (500 WM), dexamethasone (1 WM) and the car-
bohydrates indicated in the ¢gures. Cell extract luciferase activity was
determined using a Luciferase Assay Reagent (Promega) and normal-
ised by L-galactosidase activity [22]. Statistical analysis was performed
using the InStat program.
3. Results
In RNA isolated from INS-1 cells a G6Pase transcript was
detectable by RT-PCR. The RT-PCR products obtained from
INS-1 cell RNA, possessed a similar size to those obtained
from liver RNA and hybridised to a full-length G6Pase
cDNA probe (Fig. 1a). Similar results were obtained with
pancreatic RNA (data not shown). To characterise the 5P-
end of the G6Pase transcript in INS-1 cells RNase protection
and primer extension assays were performed. Primer extension
analysis (Fig. 1b) revealed that the transcription initiation site
of the G6Pase cDNA in INS-1 cells, pancreas and liver is
identical and corresponded to the start site of the rat
G6Pase mRNA reported by [20]. This was further con¢rmed
by RNase protection assays (Fig. 1c) of RNA of INS-1 cells
and liver using a probe which hybridised to exons 1 and 2 of
the hepatic transcript. With this probe products of identical
sizes were obtained from INS-1 and hepatic RNA. These re-
sults strongly indicate that the same promoter regulates
G6Pase gene transcription in INS-1 cells and liver.
Following transfection with the G6Pase promoter/luciferase
reporter gene construct pGL3-1.2 low basal luciferase activity
could be detected in INS-1 cells (Fig. 2). Incubation with the
protein kinase A activator db2cAMP and the synthetic gluco-
corticoid dexamethasone increased luciferase activity in INS-1
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Fig. 1. Characterisation of G6Pase expression in INS-1 cells. Detection of G6Pase expression in INS-1 cells (INS) and liver (Li) RT-PCR (a)
using exon-speci¢c primers as indicated and subsequent Southern blotting. Mapping of the 5P-end of G6Pase mRNA in INS-1 cells by primer
extension analysis (b). 10 Wg of total liver RNA (Li); 40 Wg of total INS-1 cell RNA (INS); 40 Wg of total pancreas RNA (Pa). Standard
DNA sequencing reactions were used as size markers. RNase protection assays (c) performed with a probe complementary to the rat liver se-
quence between nucleotides 1 to 400. DNA size marker (M); 30 Wg of total INS-1 cell RNA (INS); 5 Wg of total liver RNA (Li); undigested
probe (PROBE).
Fig. 2. Regulation of the G6Pase promoter by dexamethasone,
db2cAMP and glucose in INS-1 cells. INS-1 cells were transfected
with the plasmid pGL3-1.2 and incubated in the presence or ab-
sence of db2cAMP (DBCA) dexamethasone (Dex) with the indicated
D-glucose concentration. The normalised luciferase activity of the
promoterless pGL3 basic vector was set as 1. This background ex-
pression was not a¡ected by the glucose concentration or the hor-
mone mimetica. All values represent the mean þ S.E.M. (n = 3).
*P6 0.05 versus respective incubation with 5.5 mM glucose;
**P6 0.05 versus incubation without mediator.
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cells approximately two-fold. Dexamethasone and db2cAMP
acted synergistically. Elevating the D-glucose concentration
from 5.5 mM to 25 mM activated the G6Pase promoter ap-
proximately two-fold in INS-1 cells. This e¡ect was additive
to those of dexamethasone or db2cAMP. In HeLa cells,
MCF7 breast cancer cells and the embryonic kidney cell line
293 no expression of the reporter gene was observed after
transfection of pGL-1.2 and glucose, dexamethasone and
db2cAMP failed to induce reporter gene expression (data
not shown). This demonstrated that expression and regulation
of the reporter gene construct is tissue-speci¢c.
Several sugars were used to determine whether they were
able to mimic the activating e¡ect of D-glucose on the G6Pase
promoter in INS-1 cells (Fig. 3). The failure of L-glucose,
which cannot be taken up into the cells, to increase the pro-
moter activity, excluded osmotic e¡ects. 3-O-Methylglucose,
which is not phosphorylated, and 2-deoxyglucose, which is
phosphorylated into 2-deoxyglucose 6-phosphate, but cannot
be degraded by the Embden-Meyerho¡ pathway [16], were
not able to increase the gene promoter activity. In addition,
neither fructose nor inositol had any e¡ect. Mannose, how-
ever, was able to partly replace D-glucose. The glucokinase
inhibitor mannoheptulose [24] prevented the augmentation
of the G6Pase promoter activity by 25 mM glucose.
The inhibitor of the stress-activated protein kinase 2
(SAPK2), SB203580, caused a general stimulation of lucifer-
ase expression, but did not block the glucose e¡ect (Fig. 4).
To constrict the region in the promoter, which mediated the
glucose e¡ect, transient transfections were carried out with the
plasmid pGL (3161/+4). Using this plasmid glucose led to a
two-fold induction of reporter gene expression, from 2.5 þ 0.9
relative luciferase activity to 5.1 þ 0.3 relative luciferase activ-
ity (mean þ S.E.M., n = 4) in the presence of dexamethasone
and db2cAMP (expression of the promoterless vector pGL3
was set as 1).
4. Discussion
The data strongly suggest that INS-1 cells and liver cells
express the same transcript of the G6Pase gene using the
identical promoter. Our results do not, however, exclude the
additional presence of another isoform of G6Pase in pancreas
and INS-1 cells, which has recently been reported [25]. Incu-
bation with the protein kinase A activator db2cAMP and the
synthetic glucocorticoid dexamethasone increased luciferase
activity in INS-1 cells. These dexamethasone results are con-
sistent with previous work showing that G6Pase activity in
pancreatic L-cells is increased by dexamethasone in vivo [8].
The expression in INS-1 cells di¡ered slightly from that ob-
served after transfection of H4IIE hepatoma cells. In H4IIE
cells a higher basal expression was observed and dexametha-
sone was a more potent activator than in INS-1 cells [22].
We found the transcription of the G6Pase gene in INS-1
cells to be regulated by glucose. This indicates that the re-
cently described induction of hepatic gene expression by glu-
cose [2,3] is also caused by stimulation of gene transcription.
Several sugars were used to determine whether they were able
to mimic the activation of D-glucose on the promoter. Our
data show that the glucose e¡ect depends on phosphorylation
and glycolytic metabolism of glucose. Mannose, which can be
phosphorylated by L-cell glucokinase [24] and metabolised by
INS-1 cells [17], could mimic D-glucose to some extent. The
molecular mechanism by which glucose metabolism stimulates
G6Pase gene transcription is unclear. The cis-active element(s)
mediating the glucose e¡ect have to be localised between nu-
cleotides 3161 and +4. The human G6Pase promoter does
not contain an obvious consensus sequence for the carbohy-
drate responsive element, which is involved in the regulation
of the L-PK gene by glucose [26]. The regulation of the L-PK
gene transcription is mediated by intermediates of the pentose
FEBS 21421 18-1-99
Fig. 4. The SAPK2 inhibitor SB203580 does not prevent the regula-
tion of the G6Pase promoter by glucose. INS-1 cells transfected
with the plasmid pGL3-1.2 were incubated with a combination of
dexamethasone and db2cAMP in the presence or absence of the
SB203580 (10 WM) as indicated. The normalised luciferase activity
of the promoterless pGL3 basic vector was set as 1. All values rep-
resent the mean þ S.E.M. (n = 3). *P6 0.05 versus respective incuba-
tion with 5.5 mM glucose.
Fig. 3. E¡ect of various carbohydrates on G6Pase promoter activity
in INS-1 cells. After transfection with the reporter gene vector
pGL3-1.2 INS-1 cells were incubated in the presence of dexametha-
sone and db2cAMP and the indicated carbohydrates. D-GLUC
(5.5): 5.5 mM D-glucose; D-gluc (25): 25 mM D-glucose; MH (30):
30 mM mannoheptulose; L-gluc (20): 20 mM L-glucose; 2-DG
(20): 20 mM 2-deoxyglucose; 3-OMG (20), 20 mM 3-O-methylglu-
cose; Man (20): 20 mM mannose; Xyl (20): 20 mM xylitol; GA
(20): 20 mM glucosamine; Fruc (20): 20 mM fructose. The results
are expressed as fold stimulation compared to normalised luciferase
activity measured in the presence of 5.5 mM D-glucose, which was
set as 1.0. All values represent the mean þ S.E.M. (n = 3). *P6 0.05
versus 5.5 mM D-glucose, **P6 0.05 versus 25 mM D-glucose.
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pathway [27], because inositol [27] and 2-deoxyglucose [16] are
also active. Both carbohydrates could not replace glucose as
an activator of the G6Pase promoter. This led to the conclu-
sion that the glucose e¡ects on L-PK and G6Pase expression
are mediated by di¡erent mechanisms. The induction by glu-
cose was additive to the e¡ects of dexamethasone and
db2cAMP, suggesting that the glucocorticoid receptor or pro-
tein kinase A are not involved in the regulation by glucose.
SAPK2 has been shown to be involved in the regulation of
insulin gene transcription by glucose [28]. However, inhibition
of SAPK2 activation failed to prevent the glucose e¡ect on
G6Pase expression.
It has been suggested that the induction of hepatic G6Pase
activity by glucose serves as a mechanism by which the liver
avoids excessive glucose storage during the postprandial phase
[2,3]. There have been no reports suggesting a similar induc-
tion of G6Pase by glucose in L-cells in vivo so far. Long-term
exposure of pancreatic L-cells to high glucose concentrations
results in the induction of key glycolytic and lipogenic en-
zymes and promotes glycogen deposition [15^18]. These ef-
fects were studied using INS-1 cells as an in vitro model. It
might be that a possible induction of G6Pase in islets could
have a similar function to that in liver, i.e. protection against
high glucose load. In vivo an induction of G6Pase by glucose
may be able to modulate the glucose mediated insulin secre-
tion due to an increased glucose cycling.
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